Israel: Virginia center joins Biocancell ovarian cancer study

Biocancell develops personalized, targeted therapy that destroys tumor cells without affecting adjacent healthy tissue.
Biocancell Therapeutics Ltd. (TASE:BICL) today announced that the Massey Cancer Center in Richmond, Virginia, has obtained the final permits to begin the Phase I/IIa clinical trial of the company's BC-819 drug for the treatment of ovarian cancer. Biocancell and Massey have signed a contract to conduct the trial, and Massey has begun recruiting patients.

The trial will test the safety and effectiveness of BC-819 on women suffering from advanced ovarian cancer, who had not responded to standard treatments. Biocancell plans to recruit 12 patients for the trial. They will undergo nine treatments with BC-819 once a week. Patients who respond favorably to the treatment will then undergo additional monthly treatments. Five medical centers are currently participating in the trial: the Hadassah Medical Center, Wolfson Medical Center, and Meir Hospital in Israel; and the University of Pennsylvania Medical Center, and the Massey Cancer Center in the US. The Office of the Chief Scientist is partly financing the trial.

Biocancell develops personalized, targeted therapy that destroys tumor cells without affecting adjacent healthy tissue. The therapy is based on the identification of genes that express only in the tumors, but not healthy cells. [...]
Source: Globes

Biocancell jumps on clinical trial success (lung cancer)

Biocancell Therapeutics Ltd. (TASE:BICL) today notified the Tel Aviv Stock Exchange (TASE) that it had successfully completed a clinical trial on laboratory mice for the effectiveness of its lung cancer treatment BC-819. The company's share jumped 25.1% to NIS 3.70.

In the trial the drug was injected into the lungs of the mice which had been induced with lung cancer. The results of the trial found that the malignant growths that had been treated by BC-819 were "significantly smaller compared with the control group that had not been treated."

Biocancell conducted the trial in Munich as part of its attempts to develop cancer drugs that destroy cancerous cells while preserving healthy cells. The company said that it would "consider continuing the development of the drug in accordance with the resources at its disposal." [...] Since that investment, Biocancell has conducted trials on ovarian cancer and the renal pelvic and has received approval for a trial on pancreatic cancer.
Lire l'intégralité de l'article » (Source: Globes)
Anti Boycott Israel blog: cancer poumon, cancer pancréas

Israelis develop nanotech relief from pain of osteoarthritis

Injections of tiny globules of fat using nanotechnology have been proposed by researchers at the Technion-Israel Institute of Technology and the Hebrew University of Jerusalem to treat the degenerative disease osteoarthritis, the erosion of cartilage in the joints.

The innovative technology will be presented next week at a joint workshop of Israeli and Chinese scientists at the Technion's campus in Haifa. There are about 27 million osteoarthritis patients in the US alone, and it is estimated that 80% of the population will have radiographic evidence of the disease by the age of 65.

The researchers aim to help osteoarthritis patients avoid surgery to replace damaged hip joints and minimize pain by injecting the liposomes into the joints. The liposomes were developed by Hebrew University biochemistry Prof. Yechezkel Barenholz, a world-renowned expert in lipsome fat globules who co-developed Doxil, the world's first approved nanotechnology medicine for slow-release of chemotherapy for breast and ovarian cancer that is in the process of being authorized for other cancers as well.
Lire la suite »
Anti-Boycott Israël blog : ostéoarthrite
Source: article de Judy Siegel-Itzkovich @ TJP (Health and Sci-Tech)

Biocancell: essais cliniques pour son médicament contre le cancer de l’ovaire

Biocancell Therapeutics vient d’annoncer que le premier traitement pour le cancer de l’ovaire, le médicament BC-819, venait d’entrer dans sa phase I / IIa d’essais cliniques.

Ces tests sont destinés aux patients qui ne répondent pas aux traitements standards actuels. BioCancell offrira 6 mois de traitement aux patients qui réagiront bien au médicament. [...]

BioCancell fait remarquer que le cancer de l’ovaire touche plus de 200.000 femmes chaque année dans le monde entier, et est considéré comme particulièrement meurtrier.
Lire la suite »
Anti Boycott Israel blog
Source: Israel Valley